The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody.
J&J scoops up another atopic dermatitis drug for $1.25B fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
J&J: towards acquisition of Proteologix for $850 million marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.